Navigation Links
Undertreatment of common heart condition persists despite rapid adoption of novel therapies
Date:9/21/2012

A novel blood thinner recently approved by the FDA, dabigatran (Pradaxa), has been rapidly adopted into clinical practice, yet thus far has had little impact on improving treatment rates for atrial fibrillation. This is according to a new study led by researchers from the Johns Hopkins Bloomberg School of Public Health that examined national trends in oral anticoagulant use. They found that despite rapid adoption of dabigatran for the treatment of atrial fibrillation, a large proportion of patientstwo in fivedid not receive oral anticoagulant therapy. In addition, although the majority of dabigatran utilization was for its FDA-approved indication, atrial fibrillation, an increasing proportion of use was for off-label indications such as venous thromboembolism. The results are featured in the September 2012 issue of Circulation: Cardiovascular Quality and Outcomes.

"Dabigatran has been briskly adopted into clinical practice since its October 2010 Food and Drug Administration approval for the prevention of stroke among patients with non-valvular atrial fibrillation," said G. Caleb Alexander, MD, MS, lead author of the study and a research scientist in the Bloomberg School's Department of Epidemiology. "Between 2007 and 2011, use of the oral anticoagulant warfarin declined from approximately 2.1 million quarterly physician visits to approximately 1.6 million visits while since its release, dabigatran use increased from 3.1 percent to 18.9 percent of physician visits where an oral anticoagulant was used."

Using data from the IMS National Disease and Therapeutic Index, a nationally representative audit of ambulatory providers, Alexander and colleagues quantified patterns of oral anticoagulant use among subjects between 2007 and 2011. Focusing on the oral anticoagulant drugs, dabigatran and warfarin, they examined treatment patterns by patient age, provider specialty and common indications for oral anticoagulation. Pharmacy expenditures for warfarin and dabigatran were quantified using a nationally representative audit of retail, mail order and long-term care pharmacies.

According to the National Institutes of Health, atrial fibrillation is the most common type of arrhythmia and, compared with their counterparts, patients with atrial fibrillation have an increased risk of stroke. Previous research has indicated the use of oral anticoagulants may reduce the risk of thromboembolic events like stroke by up to two-thirds and is especially vital in the prevention of such events among high-risk individuals.

The authors conclude that, "a better understanding of how these therapies are being applied in the real world is an important step in understanding their potential to ultimately improve care."


'/>"/>

Contact: Natalie Wood-Wright
nwoodwri@jhsph.edu
410-614-6029
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Related medicine news :

1. Texting in College Classrooms Common, Distracting
2. Recovery from propofol anesthesia may be sped by use of common stimulant
3. Long-term neuropsychological impairment is common in acute lung injury survivors
4. Overuse Injuries Common Among Female College Athletes
5. Common Blood Pressure Drug Safe for Heart Failure: Study
6. Test links strains of common parasite to severe illness in US newborns
7. Common Plastics Chemical Might Boost Diabetes Risk
8. Off-Label Drug Use Appears Common
9. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
10. Slow-growing babies more likely in normal-weight women; Less common in obese pregnancies
11. Common Blood Pressure Drugs May Not Cut Colon Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
Breaking Medicine Technology: